Novartis licenses mRNA autoimmune therapy from Abogen for up to $7.8 billion
Novartis will pay $500 million upfront and up to $7.3 billion in milestones to license an mRNA-based autoimmune therapy from China's Abogen Biosciences, marking one of the largest biotech deals involving a Chinese company.
